Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of ...

Research and Development Expenses-- $4,700,000 compared to $5,600,000 during the prior year comparable period. Kodiak PCR ...

Diagnostics' progress on their PCR platform, with key trials in 2025 and commercialization plans by 2026, targeting U.S. and global markets.

An unusual about-face that played out at the FDA over the last week illustrated the power of the “Make America Healthy Again” ...

Vonaprument selected by EMA for the exclusive Product Development Coordinator (PDC) pilot launched in July 2025 to help Priority Medicine (PRIME) designation holders efficiently navigate regulatory ...

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development ...

Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the ...

Europe, Ukraine hope for chilly Putin summit ▪ The Hill interview: Newsom defends redistricting fight ▪ Progressives take center stage in mayoral contests ▪ Israel steps up ...

Sensex and Nifty close higher; top stocks post earnings, announce deals, and win contracts. Explore today's key market movers ...

Dermatologists say that oral minoxidil pills are one of the most effective treatments available for hair loss in women. Why ...